• Mashup Score: 0
    FDA Approves Expanded Indication for Leqvio - 9 month(s) ago

    July 10, 2023 — Novartis announced that the US Food and Drug Administration (FDA) has approved a label update for Leqvio (inclisiran) to enable earlier use in patients with elevated LDL-C who have an increased risk of heart disease, as an adjunct to diet and statin therapy1. This patient population includes those who have comorbidities such as hypertension and diabetes and have not yet had a…

    Source: DAIC
    Categories: Cardiologists, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of DAICeditor
      DAICeditor

      @DAICeditor @NovartisOncMed #Leqvio can now be used earlier in #LDL_C treatment as an adjunct to diet and #statintherapy for patients who have not had a ##cardiovascular event but are at an increased risk of heart: https://t.co/erQvs56Oc6

  • Mashup Score: 2
    USPSTF statin recommendations for primary prevention mostly unchanged since 2016 - 2 year(s) ago

    The U.S. Preventive Services Task Force’s new recommendation statement on the use of statin therapy for primary prevention in adults aged 40 to 75 years with no history of CVD is similar to its 2016 recommendations.The USPSTF continues to recommend statins for the primary prevention of CVD in patients aged 40 to 75 years with at least one CVD risk factor and 10% or greater 10-year risk for

    Source: www.healio.com
    Categories: Cardiology News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CardiologyToday
      CardiologyToday

      The U.S. Preventive Services Task Force’s new recommendation statement on the use of #statintherapy for #primaryprevention in adults aged 40 to 75 years with no history of CVD is similar to its 2016 recommendations @TuftsMedicalCtr #USPSTF #CardioTwitter https://t.co/UUAt5QeISk